Sientra (NASDAQ:SIEN) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Wednesday, January 16th.
A number of other analysts have also recently commented on the company. Zacks Investment Research cut Sientra from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Maxim Group upgraded Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, December 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $22.50.
Shares of NASDAQ:SIEN opened at $10.25 on Wednesday. Sientra has a 1 year low of $8.79 and a 1 year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77. The firm has a market cap of $293.14 million, a PE ratio of -3.63 and a beta of -0.03.
Large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Sientra during the fourth quarter worth about $29,000. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Sientra during the second quarter worth about $160,000. Accredited Investors Inc. purchased a new stake in shares of Sientra during the third quarter worth about $200,000. MetLife Investment Advisors LLC purchased a new stake in shares of Sientra during the second quarter worth about $226,000. Finally, Tarbox Family Office Inc. grew its position in shares of Sientra by 595.3% during the third quarter. Tarbox Family Office Inc. now owns 9,734 shares of the medical instruments supplier’s stock worth $232,000 after purchasing an additional 8,334 shares in the last quarter. Hedge funds and other institutional investors own 86.77% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: Liquidity
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.